blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1068357

EP1068357 - THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  07.11.2014
Database last updated on 11.09.2024
Most recent event   Tooltip21.10.2016Change - lapse in a contracting state
State(s) deleted from list of lapses: LU		published on 23.11.2016  [2016/47]
Applicant(s)For all designated states
NorthWest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814 / US
[2011/36]
Former [2001/03]For all designated states
NorthWest Biotherapeutics, Inc.
Suite 236, 120 Northgate Plaza
Seattle, WA 98125 / US
Inventor(s)01 / MURPHY, Gerald, P.
1134 23rd Avenue E
Seattle, WA 98112 / US
02 / BOYNTON, Alton, L.
2420 274th Avenue N.E.
Redmond, WA 98053 / US
03 / SEHGAL, Anil
Apartment H106
2104 North 105th Street
Seattle, WA 98133 / US
 [2011/38]
Former [2001/03]01 / MURPHY, Gerald, P.
1134 23rd Avenue E
Seattle, WA 98112 / US
02 / BOYNTON, Alton, L.
2420 274th Avenue N.E.
Redmond, WA 98053 / US
03 / SEHGAL, Anil
Apartment H106, 2104 North 105th Street
Seattle, WA 98133 / US
Representative(s)Gowshall, Jonathan Vallance, et al
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
[N/P]
Former [2014/50]Gowshall, Jonathan Vallance, et al
Forresters
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2012/13]Gowshall, Jonathan Vallance, et al
Forrester & Boehmert
SkyGarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2008/44]Gowshall, Jonathan Vallance, et al
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Former [2001/03]Gowshall, Jonathan Vallance, et al
FORRESTER & BOEHMERT Franz-Joseph-Strasse 38
80801 München / DE
Application number, filing date99916365.229.03.1999
[2001/03]
WO1999US07431
Priority number, dateUS19980079916P30.03.1998         Original published format: US 79916 P
US19980104656P16.10.1998         Original published format: US 104656 P
[2001/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9950461
Date:07.10.1999
Language:EN
[1999/40]
Type: A1 Application with search report 
No.:EP1068357
Date:17.01.2001
Language:EN
The application published by WIPO in one of the EPO official languages on 07.10.1999 takes the place of the publication of the European patent application.
[2001/03]
Type: B1 Patent specification 
No.:EP1068357
Date:21.09.2011
Language:EN
[2011/38]
Type: B2 New European patent specification 
No.:EP1068357
Date:10.12.2014
Language:EN
[2014/50]
Search report(s)International search report - published on:US07.10.1999
(Supplementary) European search report - dispatched on:EP03.06.2003
ClassificationIPC:C12Q1/68, G01N33/53, C07K16/00, C12N15/11, C12N15/85, C07H21/04, A61K39/395, A61K48/00
[2001/03]
CPC:
A61K31/713 (EP,US); A61K45/06 (US); A61P17/02 (EP);
A61P35/00 (EP); A61P35/02 (EP); C07K14/7158 (EP,US);
C07K16/24 (EP,US); C07K16/2866 (EP,US); A01K2217/075 (EP,US);
A61K2039/505 (EP,US); A61K38/00 (EP,US); C07K2317/73 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2001/03]
TitleGerman:THERAPEUTISCHE UND DIAGNOSTISCHE ANWENDUNGEN WELCHE AUF DER ROLLE VON CXCR-4 IN DER TUMORGENESE BASIEREN[2001/03]
English:THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS[2001/03]
French:APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES BASEES SUR LE ROLE DU GENE CXCR-4 DANS L'ONCOGENESE[2001/03]
Entry into regional phase30.10.2000National basic fee paid 
30.10.2000Search fee paid 
30.10.2000Designation fee(s) paid 
30.10.2000Examination fee paid 
Examination procedure26.10.1999Request for preliminary examination filed
International Preliminary Examining Authority: US
30.10.2000Examination requested  [2001/03]
21.12.2000Amendment by applicant (claims and/or description)
09.03.2006Despatch of a communication from the examining division (Time limit: M06)
19.09.2006Reply to a communication from the examining division
27.02.2008Despatch of a communication from the examining division (Time limit: M06)
04.06.2008Observations by third parties
29.08.2008Reply to a communication from the examining division
12.04.2010Cancellation of oral proceeding that was planned for 16.04.2010
16.04.2010Date of oral proceedings (cancelled)
12.01.2011Communication of intention to grant the patent
05.05.2011Fee for grant paid
05.05.2011Fee for publishing/printing paid
Divisional application(s)EP10184637.6  / EP2308996
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.03.2006
Opposition(s)Opponent(s)01  21.06.2012  28.06.2012  ADMISSIBLE
PIERRE FABRE MEDICAMENT
45, Place Abel Gance
92100 Boulogne-Billancourt / FR
Opponent's representative
Regimbeau, et al, et al
20, rue de Chazelles
75847 Paris Cedex 17 / FR
 [2012/51]
Former [2012/31]
Opponent(s)01  21.06.2012  28.06.2012  ADMISSIBLE
PIERRE FABRE MEDICAMENT
45, Place Abel Gance
92100 Boulogne-Billancourt / FR
Opponent's representative
Faivre Petit, Frédérique, et al, et al
Cabinet Regimbeau 20, rue de Chazelles
75847 Paris Cedex 17 / FR
30.07.2012Invitation to proprietor to file observations on the notice of opposition
02.04.2013Reply of patent proprietor to notice(s) of opposition
19.03.2014Date of oral proceedings
04.04.2014Despatch of minutes of oral proceedings
17.04.2014Despatch of interlocutory decision in opposition
24.07.2014Legal effect of interlocutory decision in opposition
14.08.2014Despatch of communication that the patent will be maintained as amended
28.10.2014Fee for printing new specification paid
Appeal following opposition27.06.2014Appeal received No.  T1429/14
24.07.2014Result of appeal procedure: appeal of the opponent withdrawn
Fees paidRenewal fee
08.03.2001Renewal fee patent year 03
22.03.2002Renewal fee patent year 04
03.04.2003Renewal fee patent year 05
22.03.2004Renewal fee patent year 06
22.03.2005Renewal fee patent year 07
29.03.2006Renewal fee patent year 08
27.09.2007Renewal fee patent year 09
27.03.2008Renewal fee patent year 10
06.03.2009Renewal fee patent year 11
17.09.2010Renewal fee patent year 12
26.07.2011Renewal fee patent year 13
Penalty fee
Additional fee for renewal fee
31.03.200305   M06   Fee paid on   03.04.2003
31.03.200709   M06   Fee paid on   27.09.2007
31.03.201012   M06   Fee paid on   17.09.2010
31.03.201113   M06   Fee paid on   26.07.2011
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipPT23.01.2012
AT29.03.2012
CY29.03.2012
FI29.03.2012
IE29.03.2012
SE30.03.2012
BE31.03.2012
DK31.03.2012
MC31.03.2012
NL01.10.2012
[2016/47]
Former [2015/26]PT23.01.2012
AT29.03.2012
CY29.03.2012
FI29.03.2012
IE29.03.2012
SE30.03.2012
BE31.03.2012
DK31.03.2012
MC31.03.2012
NL01.10.2012
LU29.03.2014
Former [2014/48]PT23.01.2012
AT29.03.2012
CY29.03.2012
FI29.03.2012
IE29.03.2012
SE30.03.2012
BE31.03.2012
DK31.03.2012
MC31.03.2012
NL01.10.2012
GR08.10.2012
LU29.03.2014
Former [2013/36]PT23.01.2012
AT29.03.2012
CY29.03.2012
FI29.03.2012
IE29.03.2012
SE30.03.2012
BE31.03.2012
DK31.03.2012
MC31.03.2012
NL01.10.2012
GR08.10.2012
Former [2012/23]PT23.01.2012
Documents cited:Search[E]WO9947158  (UNIV BRITISH COLUMBIA [CA], et al) [E] 1-14* the whole document *;
 [XP]  - SEHGAL ANIL ET AL, "CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells.", JOURNAL OF SURGICAL ONCOLOGY, (199810), vol. 69, no. 2, ISSN 0022-4790, pages 99 - 104, XP009010567 [XP] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1096-9098(199810)69:2<99::AID-JSO10>3.0.CO;2-M
 [XP]  - SEHGAL ANIL ET AL, "Molecular characterization of CXCR-4: A potential brain tumor-associated gene.", JOURNAL OF SURGICAL ONCOLOGY, (199812), vol. 69, no. 4, ISSN 0022-4790, pages 239 - 248, XP009010566 [XP] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1096-9098(199812)69:4<239::AID-JSO9>3.0.CO;2-U
International search[X]US5563048  (HONJO TASUKU [JP], et al);
 [X]WO9728258  (NAT INST HEALTH [US]);
 [X]WO9749424  (UNIV PENNSYLVANIA [US]);
 [XP]WO9817308  (IMMUSOL INC [US], et al);
 [XP]  - KUSUNOKI A., ET AL., "INHIBITION OF THE PRODUCTION OF HIV-1 SECOND RECEPTOR CXCR4 BY ANTISENSE TECHNOLOGY.", Nucleic Acids Symposium Series, Oxford University Press, GB, GB, (19980901), no. 39., ISSN 0261-3166, page 263/264., XP002921359
 [X]  - MCKNIGHT A., ET AL., "INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS FUSION BY A MONOCLONAL ANTIBODY TO A CORECEPTOR (CXCR4) IS BOTH CELL TYPE AND VIRUS STRAIN DEPENDENT.", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, US, (19970201), vol. 71., no. 02., ISSN 0022-538X, pages 1692 - 1696., XP002921360
by applicant   - PARKER ET AL., CA CANCER J. CLIN., (1996), vol. 46, pages 5 - 28
    - ENGELHARD ET AL., NEUROSURGERY, (1997), vol. 41, page 886
    - HARIHABU ET AL., J. BIOL. CHEM., (1997), vol. 272, page 28726
    - NOMURA ET AL., INT. IMMUNOL., (1993), vol. 5, page 1239
    - FEDERSPPIEL ET AL., GENOMICS, (1993), vol. 16, page 707
    - LOCTSCHER ET AL., J. BIOL. CHEM., (1994), vol. 269, page 232
    - DORANZ ET AL., IMMUNOL. RESH., (1997), vol. 16, page 15
    - FENG ET AL., SCIENCE, (1996), vol. 272, page 872
    - DORANZ ET AL., IMMUNOL. RES., (1997), vol. 16, page 15
    - ANN. REV. NEUROSCI., vol. 4, pages 17 - 42
OppositionWO9948528
    - SEHGAL A. ET AL, PROC. AMER. ASSOC. CANCER RESEARCH /ABSTRACT #1556, (19980328), vol. 39, page 228
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.